Pyronaridine/artesunate

Drug Profile

Pyronaridine/artesunate

Alternative Names: Artesunate/pyronaridine; M-PA01; PANDA; Pyramax

Latest Information Update: 30 Nov 2015

Price : $50

At a glance

  • Originator Medicines for Malaria Venture; Shin Poong Pharmaceutical
  • Class Antimalarials; Naphthyridines; Peroxides; Sesquiterpenes; Small molecules
  • Mechanism of Action Free radical stimulants; Hemeprotein inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 23 Nov 2015 The European Medicines Agency recommends approval of pyronaridine/artesunate under Article 58 for Malaria (In children) in European Union
  • 14 Apr 2015 No recent reports on development identified - Preregistration for Malaria in Myanmar (PO, tablet)
  • 31 Mar 2015 Preregistration for Malaria (In children) in European Union (PO, granule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top